C. Shi

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Chang‐xin Shi, Chang Xin Shi, Changxin Shi, Chang-xin Shi, C. X. Shi, C X Shi, C-x Shi
Publication record
102 papers · 4,372 citations · H-index 29

PAPERS

Variations in microstructure and mechanical properties along thickness direction in a heavy high strength low alloy steel plate
202319 citationsauthor #3
The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversity
20234 citationsauthor #9
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease
202313 citationsauthor #5
Transcriptional profiles define drug refractory disease in myeloma
20222 citationsauthor #4
CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IS ASSOCIATED WITH FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH EARLY VASCULAR AGING
20222 citationsauthor #5
Abstract 5588: PD-1 blockade synergizes with IMiDs to enhance bispecific T cell engager immune responses to Vk*MYChCRBN multiple myeloma by preventing T cell exhaustion
20221 citationsauthor #5
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model
20220 citationsauthor #7
IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma
20220 citationsauthor #5
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy
202115 citationsauthor #13
Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma.
20215 citationsauthor #12
Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma
20211 citationsauthor #4
IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
202056 citationsauthor #5
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity
202027 citationsauthor #1
Ex vivo sensitivity to venetoclax is predictive of clinical activity
20192 citationsauthor #8
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
201977 citationsauthor #2
The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity
20191 citationsauthor #1
Identification of PIKfyve kinase as a target in multiple myeloma
201934 citationsauthor #6
HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma
201827 citationsauthor #6
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
201753 citationsauthor #1
Loss of FAM46C Promotes Cell Survival in Myeloma.
201761 citationsauthor #2
Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.
201747 citationsauthor #4
Combined venetoclax and alvocidib in acute myeloid leukemia
201785 citationsauthor #5
Characterization of the novel protein KIAA0564 (Von Willebrand Domain-containing Protein 8).
201719 citationsauthor #7
IKZF1/3 and CRL4CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma
20172 citationsauthor #6
Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides Short title: Sequencing Reveals Natural History of Myeloma
20160 citationsauthor #2
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
201653 citationsauthor #5
Additional file 1: Figure S1. of Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
20160 citationsauthor #6
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
201639 citationsauthor #6
Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)
20162 citationsauthor #4
The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice.
201657 citationsauthor #10
Abstract 3625: Expression of CRBN binding protein AGO2 plays important roles for myeloma cell growth
20150 citationsauthor #6
Immunomodulatory Drugs Inhibit H2O2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity
20150 citationsauthor #4
Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells
20153 citationsauthor #1
Identification of FAM46C As a Multiple Myeloma Repressor
20153 citationsauthor #2
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P)
201552 citationsauthor #6
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease
201548 citationsauthor #7
Targeted sequencing of relapsed/refractory myeloma patients identifies an enrichment of mutations in MAPK and Cereblon pathways
20151 citationsauthor #10
Chromosome Condensation 1-Like (Chc1L) Is a Novel Tumor Suppressor Involved in Development of Histiocyte-Rich Neoplasms
20153 citationsauthor #5
Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways
20150 citationsauthor #10
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
201520 citationsauthor #4
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma
201529 citationsauthor #1
Cereblon binding molecules in multiple myeloma.
201546 citationsauthor #3
Ikaros expression levels to predict response and survival following pomalidomide and dexamethasone in multiple myeloma (MM).
20140 citationsauthor #3
Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements
201420 citationsauthor #9
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.
201463 citationsauthor #3
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
2014213 citationsauthor #3
The clinical significance of cereblon expression in multiple myeloma.
2014109 citationsauthor #5
Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice.
201412 citationsauthor #11
and determinants of response in myeloid malignancies
20142 citationsauthor #6
Ikaros Degradation Efficiency Correlates with Response of Multiple Myeloma (MM) Cells to IMiD Therapy and Is Blocked By Proteasome Inhibitors
20143 citationsauthor #1
LYMPHOID NEOPLASIA RNA interference screening identi fi es lenalidomide sensitizers in multiple myeloma , including RSK 2
20140 citationsauthor #4
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease
201358 citationsauthor #9
Abstract C41: Chc1L is a tumor suppressor involved in development of histiocyte-rich neoplasms
20130 citationsauthor #3
A Synthetic Lethality Druggable Genome RNAi Screen Identifies Genes Mediating Sensitivity To Lenalidomide In Multiple Myeloma Including RSK2
20130 citationsauthor #3
Intracellular Accumulation Of Light Chains Caused By Lenalidomide, and Mediated Via CRBN, Causes Major ER Stress and Is Implicated In The Synergistic Combination Of Imids and Proteasome Inhibitors
20130 citationsauthor #5
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
2012390 citationsauthor #2
Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4
20121 citationsauthor #2
Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma
201223 citationsauthor #5
Development of a Second-Generation, Helper-Dependent Adenovirus-Based Model of Glaucoma
20120 citationsauthor #2
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
2012125 citationsauthor #4
Therapeutics , Targets , and Chemical Biology Identi fi cation of Molecular Vulnerabilities in Human Multiple MyelomaCells byRNA InterferenceLethality Screeningof the Druggable Genome
20120 citationsauthor #4
The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways
20123 citationsauthor #3
Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276
20122 citationsauthor #6
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
2011578 citationsauthor #3
RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells,
20117 citationsauthor #2
[In vitro transgenic expression efficacy of a helper-dependent adenoviral vector encoding enhanced green fluorescent protein].
20100 citationsauthor #6
Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice.
201012 citationsauthor #6
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.
2010112 citationsauthor #5
Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1
201029 citationsauthor #6
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
2009116 citationsauthor #3
Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.
20091 citationsauthor #4
Prolonged Peritoneal Gene Expression Using a Helper-Dependent Adenovirus
200924 citationsauthor #2
[Advances in helper-dependent adenoviral vector--a review review].
20092 citationsauthor #3
B507 Lethal and Bortezomib-Sensitizing Targets in Myeloma Identified by Genome-Scale RNAi Screening
20090 citationsauthor #4
NF-Identification of a potent natural triterpenoid inhibitor of proteosome
20090 citationsauthor #4
Cyproheptadine displays preclinical activity in myeloma and leukemia.
200853 citationsauthor #15
Restoration of Vitamin C Synthesis in Transgenic Gulo−/− Mice by Helper-Dependent Adenovirus-Based Expression of Gulonolactone Oxidase
200815 citationsauthor #2
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
200865 citationsauthor #3
The Blimp-1 gene regulatory region directs EGFP expression in multiple hematopoietic lineages and testis in mice
200810 citationsauthor #4
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
200898 citationsauthor #4
Kinome and Druggable Genome Vulnerabilities in Multiple Myeloma Identified by Systematic RNA Interference Screening.
20072 citationsauthor #5
[Construction and preparation of helper-dependent adenoviral vector expressing human respiratory syncytial virus F gene].
20070 citationsauthor #3
PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.
20073 citationsauthor #3
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin.
200760 citationsauthor #7
Genetic Disruption of the SH3 and SAM Domains of HACS1 Enhances Adaptive Immunity.
20070 citationsauthor #6
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
20071,069 citationsauthor #9
upregulation of ubiquitin expression by increasing its proteasomal degradation through A chemical biology screen identifies glucocorticoids that regulate
20070 citationsauthor #7
RNAi Screen of the Druggable Genome To Identify Modulators of Bortezomib in Myeloma.
20071 citationsauthor #6
A Chemical Biology Screen Identifies Glucocorticoids as Inhibitors of C-Maf and C-Maf-Dependent Transactivation of Cyclin D2.
20063 citationsauthor #5
A convenient plasmid system for construction of helper‐dependent adenoviral vectors and its application for analysis of the breast‐cancer‐specific mammaglobin promoter
200628 citationsauthor #1
654. Targeting Adenoviral Vectors for Use in Breast Cancer Gene Therapy
20060 citationsauthor #3
High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.
20060 citationsauthor #7
Promiscuous Mutations Frequently Activate the Non-Canonical NFkB Pathway in Multiple Myeloma (MM).
20066 citationsauthor #13
694. Breast Cancer Specificity, Anti-Tumor Activity, and Reduced Toxicity of an Adenoviral Vector Encoding Interleukin-2 under Control of the Human Mammaglobin Promoter
20050 citationsauthor #2
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
200495 citationsauthor #2
Targeting Hematopoietic Cells Using a Blimp-1 Promoter Helper Dependent Adenoviruses.
20040 citationsauthor #1
The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
200413 citationsauthor #1
Transgenic Blimp-1 Promoter Directs Hematopoietic Specific Gene Expression in Mice.
20040 citationsauthor #6
[Sequencing of adenovirus type 7 vaccine strain fragment and characterization of the hexon encoding gene].
20031 citationsauthor #4
The use of three hemophilia A mouse models to illustrate strain-specific differences in immune responses to FVIII protein replacement via protein infusion or adenoviral gene therapy
20031 citationsauthor #3

TIMELINE

2001 1 citations

2002 39 citations

2003 2 citations

2004 108 citations

2005 0 citations

2006 37 citations

2007 1,135 citations

2008 241 citations

2009 143 citations

2010 153 citations

2011 585 citations

2012 544 citations

2013 58 citations

2014 422 citations

2015 205 citations

2016 151 citations

2017 267 citations

2018 27 citations

2019 114 citations

2020 83 citations

2021 21 citations

2022 5 citations

2023 36 citations

C. Shi

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT